Page 33 - TD-3-4
P. 33

Tumor Discovery                                                        Expert consensus of NUT carcinoma



               doi: 10.1016/j.bulcan.2022.01.015                  doi: 10.1053/j.semnuclmed.2014.07.004
            29.  Charlab R, Racz R. The expanding universe of NUTM  fusions   41.  Gasljevic G, Matter MS, Blatnik O, Unk M, Dirnhofer  S.
                                                    1
               in pediatric cancer. Clin Transl Sci. 2023;16(8):1331-1339.  NUT carcinoma: A  clinical, morphological and
               doi: 10.1111/cts.13535                             immunohistochemical  mimicker-the  role  of  RNA
                                                                  sequencing in the diagnostic procedure. Int J Surg Pathol.
            30.  Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic   2022;30(3):273-277.
               features  and  long-term  outcomes  of  NUT  midline
               carcinoma. Clin Cancer Res. 2012;18(20):5773-5779.     doi: 10.1177/10668969211047981
               doi: 10.1158/1078-0432.CCR-12-1153              42.  Moreno V, Saluja  K, Pina-Oviedo  S. NUT carcinoma:
                                                                  Clinicopathologic features, molecular genetics and
            31.  Virarkar M, Mallery M, Saleh M, Ramani NS, Morani AC,   epigenetics. Front Oncol. 2022;12:860830.
               Bhosale P. Clinical, radiographic, pathologic characterization
               and survival outcomes of nuclear protein of the testis      doi: 10.3389/fonc.2022.860830
               carcinoma. J Comput Assist Tomogr. 2021;45(3):431-441.  43.  French CA. NUT carcinoma: Clinicopathologic features,
               doi: 10.1097/RCT.0000000000001163                  pathogenesis, and treatment.  Pathol Int. 2018;68(11):583-
                                                                  595.
            32.  Polsani A, Braithwaite KA, Alazraki AL, Abramowsky C,
               Shehata BM. NUT midline carcinoma: An imaging case series      doi: 10.1111/pin.12727
               and review of literature. Pediatr Radiol. 2012;42(2):205-210.  44.  Allison DB, Rueckert J, Cornea V, Lee CY, Dueber J,
               doi: 10.1007/s00247-011-2272-3                     Bocklage   T. Thyroid carcinoma with NSD3::NUTM1
                                                                  fusion: A  Case with thyrocyte differentiation and colloid
            33.  Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A. NUT   production. Endocr Pathol. 2022;33(2):315-326.
               carcinoma of the lung. Semin Diagn Pathol. 2021;38(5):72-82.
                                                                  doi: 10.1007/s12022-021-09700-2
               doi: 10.1053/j.semdp.2021.06.005
                                                               45.  Haack H, Johnson LA, Fry CJ,  et  al. Diagnosis of NUT
            34.  Nelson BA, Lee EY, French CA, Bauer DE, Vargas SO. BRD4-  midline  carcinoma  using  a  NUT-specific  monoclonal
               NUT carcinoma of the mediastinum in a pediatric patient:   antibody. Am J Surg Pathol. 2009;33(7):984-991.
               Multidetector computed tomography imaging findings.
               J Thorac Imaging. 2010;25(3):W93-W96.              doi: 10.1097/PAS.0b013e318198d666
               doi: 10.1097/RTI.0b013e3181b5d84d               46.  McEvoy CR, Fox SB, Prall O. Emerging entities in NUTM1-
                                                                  rearranged neoplasms.  Genes Chromosomes Cancer.
            35.  Teo M, Crotty P, O’Sullivan M, French CA, Walshe JM.   2020;59(6):375-385.
               NUT midline carcinoma in a young woman. J Clin Oncol.
               2011;29(12):e336-e339.                             doi: 10.1002/gcc.22838
               doi: 10.1200/JCO.2010.32.7486                   47.  French CA, Cheng ML, Hanna GJ, et al. Report of the first
                                                                  international symposium on NUT carcinoma. Clin Cancer
            36.  Orman G, Masand P, Hicks J, Huisman TAGM,        Res. 2022;28(12):2493-2505.
               Guillerman  RP. Pediatric thoracic mass lesions: Beyond the
               common. Eur J Radiol Open. 2020;7:100240.          doi: 10.1158/1078-0432.CCR-22-0591
               doi: 10.1016/j.ejro.2020.100240                 48.  Huang Y, Durall RT, Luong NM,  et al. EZH2 synergizes
                                                                  with BRD4-NUT to drive NUT carcinoma growth through
            37.  Chen J, Li M, Lu H. Nuclear protein in testis carcinoma of   silencing of key tumor suppressor genes. bioRxiv [Preprint].
               the lung. Transl Oncol. 2023;30:101640.            2023.
               doi: 10.1016/j.tranon.2023.101640                  doi: 10.1101/2023.08.15.553204
            38.  Chang AI, Kim TS, Han J, Kim TJ, Choi JY. NUT midline   49.  Barletta JA, Gilday SD, Afkhami M, et al. NUTM1 -rearranged
               carcinoma of the lung: Computed tomography findings in   carcinoma of the thyroid: A  distinct subset of NUT
               10 patients. J Comput Assist Tomogr. 2021;45(2):330-336.  carcinoma  characterized  by frequent NSD3  -  NUTM1
               doi: 10.1097/RCT.0000000000001133                  fusions. Am J Surg Pathol. 2022;46(12):1706-1715.
            39.  Huang W, Zhang Y, Yang Q,  et al. Clinical imaging of      doi: 10.1097/PAS.0000000000001967
               primary pulmonary nucleoprotein of the testis carcinoma.   50.  Alekseyenko AA, Walsh EM, Zee BM,  et al. Ectopic
               Front Med (Lausanne). 2022;9:1083206.              protein   interactions  within  BRD -chromatin
                                                                                                     4
               doi: 10.3389/fmed.2022.1083206                     complexes drive  oncogenic megadomain formation
                                                                  in NUT midline carcinoma.  Proc  Natl  Acad  Sci  U  S  A.
            40.  Davila D, Antoniou A, Chaudhry MA. Evaluation of
               osseous metastasis in bone scintigraphy. Semin Nucl Med.   2017;114(21):E4184-E4192.
               2015;45(1):3-15.                                   doi: 10.1073/pnas.1702086114


            Volume 3 Issue 4 (2024)                         25                                doi: 10.36922/td.4904
   28   29   30   31   32   33   34   35   36   37   38